<div><div></div><div><span><p><span>Royalty Pharma plc reported first-quarter 2026 results with revenue of $630.58M, net income of $294.69M and diluted EPS of $0.67, each higher than the prior-year quarter driven by new royalty acquisitions and stronger portfolio receipts.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current quarter</span></td><td><span>Prior year quarter</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>$630.58M</span></td><td><span>$568.25M</span></td><td><span>11%</span></td></tr><tr><td><span>Net income²</span></td><td><span>$294.69M</span></td><td><span>$239.35M</span></td><td><span>23.1%</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>$0.67</span></td><td><span>$0.55</span></td><td><span>21.8%</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Total income and other revenues”. ² Reported as “Net income attributable to Royalty Pharma plc”. ³ Reported as “Earnings per Class A ordinary share”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Revenue growth of 11% reflected a 10.3% increase in income from financial royalty assets, supported by new acquisitions and stronger royalties including cystic fibrosis and Voranigo.</span></li><li><span>Portfolio receipts rose 10.3%, aided by launches and demand for Imdelltra and Amvuttra and continued growth in Trelegy, Evrysdi and Tremfya.</span></li><li><span>Deployed $527.9M in Q1 2026 on royalties and milestone payments, including investments in Avlayah, Ziihera and new R&amp;D funding agreements.</span></li><li><span>Completed internalization of management on May 16, 2025, increasing in‑house oversight and driving higher share‑based compensation recognition.</span></li><li><span>Multiple regulatory and clinical catalysts—approvals and positive trial readouts such as Alyftrek, Spinraza high dose and Avlayah—are expected to influence future cash flows.</span></li></ul><p><span>Original SEC Filing: </span>Royalty Pharma plc [ RPRX ] - 10-Q - May. 06, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

RPRX

SBIO

<p>Royalty Pharma plc reported Q1 2026 results with revenue of $630.58M, net income of $294.69M, and diluted EPS of $0.67, all showing year-over-year increases. Revenue grew by 11% due to new royalty acquisitions and stronger portfolio receipts, particularly in cystic fibrosis and Voranigo. The company deployed $527.9M in royalties and milestone payments and completed management internalization to enhance oversight. Upcoming regulatory and clinical catalysts are expected to impact future cash flows.</p>

TradingView

Royalty Pharma PLC - CL

SPDR S&P Biotech

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VG Health

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares US Pharma

Ark Genomic Revolution ETF

Royalty Pharma plc 1Q 2026: Revenue $630.58M, EPS $0.67— 10-Q Summary